


## PHARMACEUTICAL 2023



## Arbutus Biopharma Corp Rank 176 of 446





## PHARMACEUTICAL 2023



## Arbutus Biopharma Corp Rank 176 of 446

The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Arbutus Biopharma Corp is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 87% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	151,139
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,857
Liabilities, Non-Current	1,815
Other Assets	39,210
Other Compr. Net Income	-2,153
Other Expenses	6,677
Other Liabilities	23,895
Other Net Income	444
Other Revenues	39,019
Property and Equipment	5,070
Research and Development	84,408
Selling, General and Administrative Expense	17,834

Output Variable	Value in 1000 USD
Assets	195,419
Liabilities	58,567
Expenses	108,919
Revenues	39,019
Stockholders Equity	136,852
Net Income	-69,456
Comprehensive Net Income	-70,532
Economic Capital Ratio	130%

